CN1022688C - 氟胞嘧啶核苷衍生物的制备方法 - Google Patents

氟胞嘧啶核苷衍生物的制备方法 Download PDF

Info

Publication number
CN1022688C
CN1022688C CN88107886A CN88107886A CN1022688C CN 1022688 C CN1022688 C CN 1022688C CN 88107886 A CN88107886 A CN 88107886A CN 88107886 A CN88107886 A CN 88107886A CN 1022688 C CN1022688 C CN 1022688C
Authority
CN
China
Prior art keywords
deoxidation
fluoro
cytidine
deoxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN88107886A
Other languages
English (en)
Chinese (zh)
Other versions
CN1033183A (zh
Inventor
藤生守男
石秀夫
三轮昌敬
梅田勲
横濑一辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1033183A publication Critical patent/CN1033183A/zh
Application granted granted Critical
Publication of CN1022688C publication Critical patent/CN1022688C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN88107886A 1987-11-17 1988-11-16 氟胞嘧啶核苷衍生物的制备方法 Expired - Lifetime CN1022688C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP87116926 1987-11-17
EP87116926.4 1987-11-17

Publications (2)

Publication Number Publication Date
CN1033183A CN1033183A (zh) 1989-05-31
CN1022688C true CN1022688C (zh) 1993-11-10

Family

ID=8197450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN88107886A Expired - Lifetime CN1022688C (zh) 1987-11-17 1988-11-16 氟胞嘧啶核苷衍生物的制备方法

Country Status (34)

Country Link
US (1) US4966891A (cs)
EP (1) EP0316704B1 (cs)
JP (1) JPH0678350B2 (cs)
KR (1) KR970000241B1 (cs)
CN (1) CN1022688C (cs)
AR (1) AR247217A1 (cs)
AT (1) ATE124951T1 (cs)
AU (1) AU619220B2 (cs)
CA (1) CA1327358C (cs)
CS (1) CS274486B2 (cs)
DE (2) DE10199027I2 (cs)
DK (1) DK170893B1 (cs)
DZ (1) DZ1270A1 (cs)
ES (1) ES2074429T3 (cs)
FI (1) FI89804C (cs)
GR (1) GR3017686T3 (cs)
HU (1) HU199866B (cs)
IE (1) IE883430L (cs)
IL (1) IL88363A0 (cs)
IS (1) IS1895B (cs)
LT (1) LT2185B (cs)
LU (1) LU90769I2 (cs)
LV (1) LV5624A3 (cs)
MC (1) MC1992A1 (cs)
MX (1) MX173347B (cs)
NL (1) NL300045I2 (cs)
NO (2) NO171167C (cs)
NZ (1) NZ226923A (cs)
PH (1) PH25641A (cs)
PT (1) PT89009B (cs)
SU (1) SU1736342A3 (cs)
UA (1) UA19333A (cs)
YU (1) YU47122B (cs)
ZA (1) ZA888428B (cs)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258360B1 (en) * 1989-05-04 2001-07-10 Igen International, Inc. Prodrugs activated by targeted catalytic proteins
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
TW254946B (cs) * 1992-12-18 1995-08-21 Hoffmann La Roche
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
IT1291983B1 (it) * 1997-05-23 1999-01-25 Pro Bio Sint Srl Prodcedimento per la preparazione di un derivato della desossiuridina
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20010051348A1 (en) * 2000-01-28 2001-12-13 Lee Chee Wee Novel ligands and methods for preparing same
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US6774758B2 (en) * 2002-09-11 2004-08-10 Kalyan P. Gokhale Low harmonic rectifier circuit
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
CA2525973A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
DK1706414T3 (da) * 2003-12-22 2008-10-13 Hoffmann La Roche Fremgangsmåde til fluorcytidinderivater
JP2007523905A (ja) * 2004-02-18 2007-08-23 アストラゼネカ アクチボラグ 化合物
EP2048137A1 (en) * 2004-02-18 2009-04-15 AstraZeneca AB Benzamide derivatives and their use as glucokinase activating agents.
CN100383128C (zh) * 2004-02-23 2008-04-23 上海迪赛诺医药发展有限公司 N4－氧羰基胞嘧啶衍生物及制备方法与应用
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GB0421294D0 (en) * 2004-09-24 2004-10-27 Angiogene Pharm Ltd Bioreductively-activated prodrugs
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
BRPI0516595A (pt) 2004-10-16 2008-09-23 Astrazeneca Ab processo para fabricar um composto, e, composto
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
NO322682B1 (no) * 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
AU2006228581A1 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
EP1891069A1 (en) * 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
EP2027113A1 (en) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
CN100569790C (zh) * 2005-07-15 2009-12-16 上海奥锐特国际贸易有限公司 合成n4-酰基-5＇-脱氧-5-氟胞苷衍生物的方法
ATE546148T1 (de) * 2005-07-21 2012-03-15 Nuvo Res Ag Stabilisierte chlorit-lösungen in kombination mit fluorpyrimidinen zur krebsbehandlung
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
MX2009006729A (es) 2006-12-21 2009-08-07 Astrazeneca Ab Nuevo compuesto cristalino util como activador de glk.
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
US20100130734A1 (en) * 2007-04-20 2010-05-27 Dr. Reddy's Laboratories Ltd. Process for preparing capecitabine
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20090122955A (ko) * 2008-01-03 2009-12-01 플러스 케미칼스, 에스.에이. 카페시타빈의 제조 방법
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
WO2010065586A2 (en) * 2008-12-02 2010-06-10 Dr. Reddy's Laboratories Ltd. Preparation of capecitabine
EP2393472B1 (en) * 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
CN101787066B (zh) * 2009-01-23 2013-07-31 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
CN101875680B (zh) * 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
CN102858791A (zh) * 2009-07-23 2013-01-02 台湾神隆股份有限公司 制备氟胞苷衍生物的方法
EP3117709B1 (en) 2010-03-12 2018-08-01 Genzyme Corporation Combination therapy for treating breast cancer
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
WO2014048939A1 (en) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US9447137B2 (en) 2012-11-07 2016-09-20 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine aryl amide analogs
WO2014145207A1 (en) * 2013-03-15 2014-09-18 Ohio State Innovation Foundation Substituted gemcitabine bicyclic amide analogs and treatment methods using same
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
CN103450301B (zh) * 2013-09-09 2015-09-09 南通大学 法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CN109414438A (zh) * 2016-06-28 2019-03-01 塞尔利克斯生物私人有限公司 用于治疗癌症的组合物和方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US11034667B2 (en) 2017-01-09 2021-06-15 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3618837A4 (en) 2017-04-26 2020-11-04 Thomas I. Kalman MULTI-DIRECTIONAL NUCLEOSIDE DERIVATIVES
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
WO2019139921A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN111801339B (zh) * 2018-01-19 2025-06-24 纽科利制药公司 5-氟尿嘧啶化合物
SG11202100411TA (en) * 2018-08-03 2021-02-25 Cellix Bio Private Ltd Compositions and methods for the treatment of cancer
CN109651467A (zh) * 2019-01-15 2019-04-19 齐鲁天和惠世制药有限公司 一种卡培他滨杂质及其制备方法
WO2021011692A1 (en) 2019-07-17 2021-01-21 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
WO2021216431A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Benzyloxy phosph(on)ate compounds
EP4143199B1 (en) 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
JP2023535225A (ja) 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
KR20230129479A (ko) 2021-01-08 2023-09-08 스트랜드 세러퓨틱스 인코포레이티드 발현 구성체 및 이의 용도
AU2023262576A1 (en) 2022-04-26 2024-10-10 Strand Therapeutics Inc. Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof
WO2025193628A2 (en) 2024-03-09 2025-09-18 Aadigen, Llc Compositions for treating cancer with kras mutations and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
GB1379410A (en) * 1971-06-08 1975-01-02 Upjohn Co 1-beta-d-arabino-furanosyl-n4-alpha-aminoacylcytosines
JPS52153977A (en) * 1976-06-11 1977-12-21 Daikin Ind Ltd Synthesis of 5-fluorouracil and its derivatives
US4071680A (en) * 1976-12-20 1978-01-31 Hoffmann-La Roche Inc. 5'-Deoxy-5-fluoropyrimidine nucleosides
CH633810A5 (en) * 1978-01-01 1982-12-31 Hoffmann La Roche Novel nucleosides and process for their preparation
FR2528311B1 (fr) * 1982-06-14 1985-06-14 Synthelabo Compositions pharmaceutiques a base de xylosides et lyxosides de bases puriques et pyrimidiques
JPS61112093A (ja) * 1984-11-05 1986-05-30 Wakunaga Seiyaku Kk ヌクレオチド誘導体

Also Published As

Publication number Publication date
IL88363A0 (en) 1989-06-30
SU1736342A3 (ru) 1992-05-23
EP0316704A2 (de) 1989-05-24
NL300045I1 (nl) 2001-08-01
DE10199027I1 (de) 2001-08-02
ES2074429T3 (es) 1995-09-16
NL300045I2 (nl) 2002-01-02
FI885329A0 (fi) 1988-11-17
PT89009B (pt) 1993-02-26
IE883430L (en) 1989-05-17
HK1003114A1 (en) 1998-10-09
ZA888428B (en) 1989-06-28
PH25641A (en) 1991-08-21
DZ1270A1 (fr) 2004-09-13
DK640388D0 (da) 1988-11-16
NO171167C (no) 1993-02-03
DK640388A (da) 1989-05-18
DE3854148D1 (de) 1995-08-17
KR890008162A (ko) 1989-07-10
HUT48267A (en) 1989-05-29
HU199866B (en) 1990-03-28
PT89009A (pt) 1988-12-01
EP0316704B1 (de) 1995-07-12
AU619220B2 (en) 1992-01-23
NO885106D0 (no) 1988-11-16
IS3412A7 (is) 1989-05-18
NO2001013I2 (no) 2006-05-01
FI89804C (fi) 1993-11-25
DE10199027I2 (de) 2002-01-31
FI89804B (fi) 1993-08-13
YU47122B (sh) 1994-12-28
NO885106L (no) 1989-05-18
CA1327358C (en) 1994-03-01
CS274486B2 (en) 1991-04-11
LT2185B (lt) 1993-10-15
IS1895B (is) 2003-10-20
AU2516888A (en) 1989-05-25
NO171167B (no) 1992-10-26
YU209188A (en) 1990-08-31
NZ226923A (en) 1990-10-26
US4966891A (en) 1990-10-30
LV5624A3 (lv) 1994-05-10
MC1992A1 (fr) 1989-11-30
CN1033183A (zh) 1989-05-31
UA19333A (uk) 1997-12-25
DK170893B1 (da) 1996-03-04
ATE124951T1 (de) 1995-07-15
JPH01153696A (ja) 1989-06-15
AR247217A1 (es) 1994-11-30
EP0316704A3 (en) 1990-11-22
CS747588A2 (en) 1990-09-12
JPH0678350B2 (ja) 1994-10-05
MX173347B (es) 1994-01-03
GR3017686T3 (en) 1996-01-31
MX13836A (es) 1993-10-01
KR970000241B1 (ko) 1997-01-08
FI885329L (fi) 1989-05-18
LU90769I2 (fr) 2001-07-02

Similar Documents

Publication Publication Date Title
CN1033183A (zh) 氟胞嘧啶核苷衍生物
CN1045088C (zh) 用作pnp抑制剂的嘌呤和鸟嘌呤化合物
CN1040761C (zh) 含乙基膦酸酯侧链的稠合含氮杂环衍生物含有它们的药物组合物及其应用
CN100347185C (zh) 新的无环核苷膦酸酯衍生物,其盐及其制备方法
CN1612889A (zh) 3－β－呋喃核糖基噻唑并[4,5－d]嘧啶核苷及其应用
CN1020107C (zh) 抗病毒化合物的制备方法
CN1195768C (zh) 3’－取代的核苷衍生物
CN1268140A (zh) 单环l－核苷、类似物及其应用
CN87105758A (zh) 嘧啶衍生物的制备方法及其用途
CN1197871C (zh) 5’－脱氧胞苷衍生物
CN1190401A (zh) C－4′修饰的腺苷激酶抑制剂
CN1094056A (zh) N-氧羰基取代的5′-脱氧-5-氟胞苷衍生物
CN1073443A (zh) 具有免疫抑制活性的大环内酯的制备方法
HK1047942A1 (zh) 嘌呤衍生物
CN1777432A (zh) 用于治疗病毒感染尤其是hiv感染的抗病毒核苷类似物和方法
CN101061111A (zh) Dna－pk抑制剂
CN1014409B (zh) 生产抗坏血酸衍生物的方法
CN1231472C (zh) 嘧啶无环核苷衍生物、其制备方法及其用途
CN1023561C (zh) 新颖的隐陡头霉素/腺苷衍生物的制备方法
CN1275966C (zh) 吡啶并吡啶并吡咯并 [ 3 , 2 － g ]吡咯并 [ 3 , 4 － e ]吲哚和吡啶并吡咯并[ 2 , 3 － a ]吡咯并 [ 3 , 4 －c ]咔唑化合物 ,其制备方法以及其药物组合物
CN1095714A (zh) 2，3-二氮杂萘酮衍生物
CN1068817A (zh) 吲哚类衍生物
CN1500800A (zh) 用作逆转录病毒的逆转录酶及dna聚合酶抑制剂的抗病毒药的核苷类似物
CN1084178A (zh) 具抗病毒和抗癌活性的2′-脱氧-2′，2′-二氟(2，6，8-取代的)嘌呤核苷以及中间体
CN1260801A (zh) 银杏内酯的新型糖基化衍生物,它们作为药物的用途及包含该衍生物的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term